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LETTER TO THE EDITOR
Successful salvage therapy for refractory 
primary cutaneous gamma-delta T-cell 
lymphoma with a combination of brentuximab 
vedotin and gemcitabine
Sophie Voruz1 , Laurence de Leval2 and Anne Cairoli1* 
Abstract 
Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a very rare lymphoma with an aggressive clinical 
course and a dismal outcome. The prognosis is linked to a pronounced resistance to chemotherapy and radiotherapy. 
No standard treatment approach is defined due to the low frequency of the disease and lack of prospective studies. 
CD30 is expressed in almost half of the cases of PCGD-TCL, which offers a potential therapeutic option. We report the 
successful treatment of a 68-year-old man who suffered PCGD-TCL with a combination of Brentuximab Vedotin and 
Gemcitabine after the failure of two lines of previous chemotherapy. CD30 expression was only partial. The treatment 
was very well tolerated and allowed the patient to benefit from allogeneic hematopoietic stem cell transplantation.
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To the Editor
Primary cutaneous gamma delta T-cell lymphoma 
(PCGD-TCL) represents < 1% of cutaneous T-cell lym-
phomas [1]. The clinical course is mostly aggressive with 
a median survival rate between 11 and 20% at 5 years 
with ranges from 15 to 31 months after diagnosis [2–4]. 
The prognosis is even worse for patients with predomi-
nantly subcutaneous fat involvement, as in this case, 
compared to those with epidermal or dermal disease 
only, reaching 10 months [2]. The prognosis is linked to 
a pronounced resistance to chemotherapy and radio-
therapy. No standard treatment approach is defined due 
to the low frequency of the disease and lack of prospec-
tive studies. Here, we report the case of a patient with 
refractory PCGD-TCL who was successfully treated with 
a combination of Brentuximab Vedotin and Gemcitabine.
A 68-year-old man presented with numerous pannicu-
litis-like thickened erythematous red-brownish painless 
cutaneous plaques that had developed over the past 3 
months. Some lesions had evolved with skin ulceration. 
They were first noticed on the lower extremities and sub-
sequently involved the trunk, the upper extremities and 
the face (Fig. 1). The patient reported no other symptoms 
and particularly no pruritus. PET scan showed multiple 
subcutaneous metabolic lesions with maximum standard 
uptake values (SUV) of 12.3 mg/l, without hepatosplenic 
or systemic involvement.
A biopsy of a calf lesion showed a lymphoid infiltrate 
involving the subcutaneous fat and extending to the 
dermis while preserving the epidermis. The infiltrate 
consisted of medium to large atypical lymphocytes 
admixed with a large number of histiocytes, featur-
ing fat cell rimming and producing a panniculitis-like 
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pattern (Fig.  2). By immunohistochemistry the lym-
phoid cells were positive for CD2 and CD3, weakly 
positive for CD56, and expressed several cytotoxic 
markers (TIA-1 granzyme B, and perforin). They were 
positive for TCR delta and negative for TCR betaF1, 
CD4, CD8, CD5, CD7 and CD57. Moderate to strong 
CD30 expression was detected in a subset of the lym-
phoid cells (< 50%). Ki67 proliferation fraction was 80%. 
PCR studies documented a monoclonal rearrangement 
of TRG and TRB genes.
A diagnosis of PCGD-TCL was established, and 
the patient was administered CHOEP chemotherapy 
and prophylactic intrathecal chemotherapy. After 2 
cycles, PET-CT showed progressive disease, and the 
patient developed B symptoms. Therapy was switched 
to B-CHP; after two cycles, no improvement was 
Fig. 1 The panniculitis-like lesions with adjacent erythematous patches and skin ulceration
Fig. 2 Histopathology of a skin biopsy. A Panoramic view showing an infiltrate predominantly involving the subcutaneous fat lobules. B 
Subcutaneous infiltrate with a panniculitis-like pattern, and focal dermal involvement. C CD3 immunostaining showing diffuse CD3 positivity 
and highlighting the subcutaneous and dermal distribution of the infiltrate. D High-power view of the subcutaneous fat showing an infiltrate of 
medium to large atypical lymphoid rimming the adipocytes and admixed to histiocytes. E Strong expression of TCR delta by the T cells. F Strong 
expression of perforin by the T cells. G Partial expression of CD30 by the T cells
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clinically observed and the PET-CT showed only a 
slight response of some of the lesions (Deauville score 
5). The patient condition worsened with ECOG 3. A 
third-line therapy was initiated with brentuximab-
vedotin (1.8 mg/kg D1) and gemcitabine (800 mg/
m2 D1 and D8). After two cycles, we observed a very 
good partial remission and the patient received four 
additional cycles very well tolerated, and recovered 
an excellent general condition. After 6 cycles, clinical 
response was almost complete; PET-CT scan showed 
very few persistent lesions with a SUVmax < 3.5 mg/l in 
the upper limbs and trunk that were difficult to inter-
prete as residual tumor versus inflammatory response. 
Nine months after the diagnosis, an allogeneic stem cell 
transplantation (ASCT) with a haplo-identical donor 
was performed after sequential clofarabine-based con-
ditioning regimen. The patient is still in clinical com-
plete response 9 months after the transplant.
Anthracycline-based treatment is often use to treat 
PCGD-TCL despite disappointing results [5]. ASCT has 
shown favorable and durable outcome for some patients 
[5–9], however maximal lowering of the disease burden 
is still necessary before proceeding to transplant. As 
CD30 is expressed in almost half of the cases of PCGD-
TCL [10], brentuximab-vedotin is a potential therapeu-
tic option. Recently, brentuximab-vedotin has shown 
efficacy in four patients, even if the expression of CD30 
was low [11]. Of note, CD30 expression was partial in our 
case. Weekly gemcitabine is an old drug regimen, very 
well tolerated in monotherapy, that has been used in a 
relapsed or refractory setting in other cutaneous T-cell 
lymphomas with notable efficacy. We thought to use the 
combination of these two drugs as it was successfully 
done in pediatric refractory Hodgkin lymphoma [12], 
since we needed a well-tolerated regimen at this point of 
the treatment.
The advantage of this treatment was its high tolerabil-
ity and its efficacy allowing the patient to benefit from 
ASCT.
Further clinical studies are needed to evaluate better 
the efficiency of this treatment and its ability to bridge to 
an ASCT in this rare T-cell lymphoma entity.
CHOEP regimen: cyclophosphamide, 750 mg/m2 i.v.; 
doxorubicin, 50 mg/m2 i.v., vincristine, 2 mg i.v on 
day 1; etoposide, 100 mg/m2/d i.v. on day 1 to 3 and 
prednisone, 100 mg/d p.o. on day 1 through 5 every 
21 days.
Prophylactic intrathecal chemotherapy: methotrex-
ate 15 mg, cytarabine 30 mg, methylprednisolone 30 
mg.
B-CHP regimen: brentuximab-vedotin, 1.8 mg/kg 
i.v.; cyclophosphamide, 750 mg/m2 i.v. and doxoru-
bicin, 50 mg/m2 i.v. on day 1; prednisone 100 mg/d 
p.o. on day 1 to 5, every 21 days.
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